Pilaralisib - Exelixis/ Sanofi

Drug Profile

Pilaralisib - Exelixis/ Sanofi

Alternative Names: SAR-245408; XL-147

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Exelixis
  • Developer Exelixis; Sanofi
  • Class Antineoplastics; Quinoxalines; Small molecules; Sulfonamides
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Breast cancer; Glioblastoma; Lymphoma; Non-small cell lung cancer; Solid tumours
  • Discontinued Endometrial cancer

Most Recent Events

  • 10 Sep 2018 Discontinued - Phase-I/II for Solid tumours (Combination therapy) in Spain, Belgium (PO) (Sanofi pipeline, September 2018)
  • 10 Sep 2018 Discontinued - Phase-I/II for Solid tumours (Monotherapy) in Belgium, France (PO) (Sanofi pipeline, September 2018)
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top